Selective induction of protection against influenza virus infection in mice by a lipid-peptide conjugate delivered in liposomes.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Vaccine

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/0264-410X(94)90287-9PMID 7975857
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Synthesis of cyclic peptides on solid support. Application to analogs of hemagglutinin of influenza virus.

  2009cited by this paper
• Lyophilized liposomes as shelf items for the preparation of immunogenic liposome-peptide conjugates.

  1993cited by this paper
• Structural and dynamic studies of two antigenic loops from haemagglutinin: A relaxation matrix approach

  1993cited by this paper
• Induction of immune response against a short synthetic peptide antigen coupled to small neutral liposomes containing monophosphoryl lipid A.

  1993cited by this paper
• A chemically defined synthetic vaccine model for HIV-1.

  1992cited by this paper
• Synthetic recombinant vaccine expressing influenza haemagglutinin epitope in Salmonella flagellin leads to partial protection in mice.

  1992cited by this paper
• Structural basis of antigenic specificity and design of new vaccines

  1992cited by this paper
• Effect of adjuvant formulations on the selection of B-cell epitopes expressed by a malaria peptide vaccine.

  1992cited by this paper
• Impact of a micellar environment on the conformations of two cyclic pentapeptides

  1992cited by this paper
• Liposomes as antigen carriers and adjuvants in vivo.

  1992cited by this paper
• Immunogenicity of free synthetic peptides corresponding to T helper epitopes of the influenza HA 1 subunit

  1992cited by this paper
• The iscom structure as an immune-enhancing moiety: experience with viral systems.

  1992cited by this paper
• Characteristics and practical use of new-generation adjuvants as an acceptable alternative to Freund's complete adjuvant.

  1992cited by this paper
• Application and limitations of the multiple antigen peptide (MAP) system in the production and evaluation of anti-peptide and anti-protein antibodies.

  1992cited by this paper
• Liposomes as carriers of antigens and adjuvants.

  1991cited by this paper
• Immunogenicity of multiple antigen peptides (MAP) containing T and B cell epitopes of the repeat region of the P. falciparum circumsporozoite protein

  1991cited by this paper
• Synthetic peptides as the basis for vaccine design.

  1991cited by this paper
• Parameters affecting the immunogenicity of a liposome‐associated synthetic hexapeptide antigen

  1991cited by this paper
• Immunological evaluation of the multiple antigen peptide (MAP) system using the major immunogenic site of foot-and-mouth disease virus.

  1991cited by this paper
• Efficacy of nucleoprotein and haemagglutinin antigens expressed in fowlpox virus as vaccine for influenza in chickens.

  1991cited by this paper
• Immunological adjuvants: a role for liposomes.

  1990cited by this paper
• Antigenic properties and protective capacity of a cyclic peptide corresponding to site A of influenza virus haemagglutinin.

  1990cited by this paper
• Liposomes containing lipid A: a potent nontoxic adjuvant for a human malaria sporozoite vaccine.

  1990cited by this paper
• Incorporation of T and B epitopes of the circumsporozoite protein in a chemically defined synthetic vaccine against malaria

  1990cited by this paper
• Effect of liposome encapsulation on antigen presentation in vitro. Comparison of presentation by peritoneal macrophages and B cell tumors.

  1989cited by this paper
• Antibodies to synthetic peptides from the preS1 region of the hepatitis B virus (HBV) envelope (env) protein are virus-neutralizing and protective.

  1989cited by this paper
• Immunoadjuvant action of liposomes for entrapped poliovirus peptide

  1989cited by this paper
• Vaccine engineering: enhancement of immunogenicity of synthetic peptide vaccines related to hepatitis in chemically defined models consisting of T- and B-cell epitopes.

  1989cited by this paper
• Efficacy of Influenza Haemagglutinin and Nucleoprotein as Protective Antigens against Influenza Virus Infection in Mice

  1988cited by this paper
• Immunogenicity of a synthetic peptide corresponding to a portion of the heavy chain of H3N2 influenza virus haemagglutinin.

  1987cited by this paper
• Non-responsiveness to a foot-and-mouth disease virus peptide overcome by addition of foreign helper T-cell determinants

  1987cited by this paper
• Effectiveness of liposomes as potential carriers of vaccines: applications to cholera toxin and human malaria sporozoite antigen.

  1986cited by this paper
• Antibodies to a synthetic peptide from the preS 120-145 region of the hepatitis B virus envelope are virus neutralizing.

  1986cited by this paper
• Synthetic peptides as antigens: pitfalls of conjugation methods.

  1985cited by this paper
• Immunological priming with synthetic peptides of foot-and-mouth disease virus.

  1985cited by this paper
• Antibodies elicited by influenza virus hemagglutinin fail to bind to synthetic peptides representing putative antigenic sites.

  1985cited by this paper
• Synthetic peptides from four separate regions of the poliovirus type 1 capsid protein VP1 induce neutralizing antibodies.

  1985cited by this paper
• Antigenic determinants of influenza virus haemagglutinin. X. A comparison of the physical and antigenic properties of monomeric and trimeric forms.

  1985cited by this paper
• A synthetic vaccine against influenza with built-in adjuvanticity.

  1985cited by this paper
• Antibodies to hepatitis B surface antigen (HBsAg) elicited by immunization with a synthetic peptide covalently linked to liposomes.

  1984cited by this paper
• Location and chemical synthesis of a pre-S gene coded immunodominant epitope of hepatitis B virus.

  1984cited by this paper
• Immunity and protection against influenza virus by synthetic peptide corresponding to antigenic sites of hemagglutinin.

  1984cited by this paper
• Functional basis of poliovirus neutralization determined with monospecific neutralizing antibodies

  1983cited by this paper
• Irreversible coupling of immunoglobulin fragments to preformed vesicles. An improved method for liposome targeting.

  1982cited by this paper
• Anti-influenza response achieved by immunization with a synthetic conjugate.

  1982cited by this paper
• Antigenic activity of a synthetic peptide comprising the "loop" region of influenza virus hemagglutinin.

  1982cited by this paper
• Immunogenic structure of the influenza virus hemagglutinin.

  1982cited by this paper
• Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 Å resolution

  1981cited by this paper
• Carrier-priming leads to hapten-specific suppression

  1980cited by this paper
• Liposomes as immunological adjuvants

  1974cited by this paper

• Immunologically Inert Nanostructures as Selective Therapeutic Tools in Inflammatory Diseases

  2021cites this paper
• Generation of a Reassortant Influenza A Subtype H3N2 Virus Expressing Gaussia Luciferase

  2019cites this paper
• Coupling of Peptides to the Surface of Liposomes— Application to Liposome-Based Synthetic Vaccines

  2016cites this paper
• Animal Models for Influenza Virus Pathogenesis and Transmission

  2010cites this paper
• Role of lipid structure in the humoral immune response in mice to covalent lipid-peptides from the membrane proximal region of HIV-1 gp41.

  2009cites this paper
• Development of influenza virosome-based synthetic malaria vaccines

  2008cites this paper
• The rational design of biological complexity: A deceptive metaphor

  2007cites this paper
• The rational design of biological complexity: A deceptive metaphor

  2007cites this paper
• Immunogenicity and Efficacy of Liposome-encapsulated Influenza Split Vaccine in BALB/c Mice

  2007cites this paper
• Synthesis of thiol-reactive lipopeptide adjuvants. Incorporation into liposomes and study of their mitogenic effect on mouse splenocytes.

  2004cites this paper
• Synthetic peptides in the diagnosis of systemic autoimmune diseases.

  2003cites this paper
• Synthetic peptide-based highly immunogenic liposomal constructs.

  2003cites this paper
• Recognition of peptides by antibodies and investigations of affinity using biosensor technology.

  2001cites this paper
• Chapter 4 – INTERACTIONS BETWEEN BILAYER VESICLES, BIOMOLECULES, AND INTERFACES

  2001cites this paper
• High immunogenicity in chimpanzees of peptides and lipopeptides derived from four new Plasmodium falciparum pre-erythrocytic molecules.

  2000cites this paper
• Differential reactivity of maleimide and bromoacetyl functions with thiols: application to the preparation of liposomal diepitope constructs.

  2000cites this paper
• 10. NIOSOMES AS IMMUNOLOGICAL ADJUVANTS

  2000cites this paper
• Molecular design versus empirical discovery in peptide-based vaccines. Coming to terms with fuzzy recognition sites and ill-defined structure-function relationships in immunology.

  1999cites this paper
• Design of highly immunogenic liposomal constructs combining structurally independent B cell and T helper cell peptide epitopes

  1999cites this paper
• Chapter 2 - Peptide-carrier conjugation

  1999cites this paper
• Complete protection of mice from respiratory syncytial virus infection following mucosal delivery of synthetic peptide vaccines.

  1999cites this paper
• A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. II. Induction of TH1 and TH2 responses in mice.

  1999cites this paper
• Stabilization of aerosolized IFN-gamma by liposomes.

  1999cites this paper
• A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. I. Vaccine characterization and efficacy studies in mice.

  1999cites this paper
• Chapter 1 - Molecular dissection of protein antigens and the prediction of epitopes

  1999cites this paper
• Chapter 3 – Immunization with peptides

  1999cites this paper
• Stabilization of aerosolized IFN-γ by liposomes

  1999cites this paper
• Molecular design versus empirical discovery in peptide-based vaccines. Coming to terms with fuzzy recognition sites and ill-defined structure-function relationships in immunology.

  1999cites this paper
• Chapter 8 – Synthetic peptides as vaccines

  1999cites this paper
• Liposomes: from membrane models to gene therapy

  1998cites this paper
• Design and synthesis of thiol-reactive lipopeptides.

  1998cites this paper
• Synthetic lipopeptides incorporated in liposomes: in vitro stimulation of the proliferation of murine splenocytes and in vivo induction of an immune response against a peptide antigen.

  1997cites this paper
• LIPOSOMES TO INDUCE POTENT HUMORALE RESPONSES TO T-INDEPENDENT ANTIGENS'

  1996cites this paper
• Lipid vesicle‐entrapped influenza A antigen modulates the influenza A‐specific human antibody response in immune reconstituted SCID‐human mice

  1996cites this paper
• Mimicry of viral epitopes with retro-inverso peptides of increased stability.

  1996cites this paper
• Synthesis of short polyoxyethylene-based heterobifunctional cross-linking reagents. Application to the coupling of peptides to liposomes.

  1996cites this paper
• Conformational display of two neutralizing epitopes of HIV-1 gp41 on the Flock House virus capsid protein.

  1996cites this paper
• Immunogenicity of new heterobifunctional cross-linking reagents used in the conjugation of synthetic peptides to liposomes.

  1996cites this paper
• Enhanced immunogenicity and cross-reactivity of retro-inverso peptidomimetics of the major antigenic site of foot-and-mouth disease virus.

  1995cites this paper
• EFFECTS OF PHOSPHOLIPID COMPOSITION ON ADJUVANT EFFICIENCY OF LIPOSOMES

  1995cites this paper
• Ability of linear and cyclic peptides of neutralization antigenic site 1 of poliovirus type 1 to induce virus cross-reactive and neutralizing antibodies.

  1994cites this paper